A Study to Evaluate the Efficacy and Safety of TP-06 for PCED
Study sponsor: Tarsus Pharmaceuticals, Inc. · TARS
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2028-07-07Estimated
Enrollment · participants32Estimated
Source updated2026-10-21Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.